Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ARG2 | P78540 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CPT2 | P23786 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27568612 | 0.98 | CYP4F2 (0.46) | CYP4F2CYP4A11TDP1LMNAHSD17B10 | |
| SCHEMBL28212418 | 0.98 | CYP4F2 (0.46) | CYP4F2CYP4A11TDP1LMNAHSD17B10 | |
| SCHEMBL27535729 | 0.98 | CYP4F2 (0.40) | CYP4F2CYP4A11TDP1LMNAHSD17B10 | |
| SCHEMBL28507146 | 0.85 | LMNA (0.38) | CYP4F2CYP4A11TDP1LMNAHSD17B10 | |
| SCHEMBL27403746 | 0.83 | LMNA (0.42) | LMNAHSD17B10 | |
| SCHEMBL27696459 | 0.83 | FDPS (0.36) | TDP1LMNAHSD17B10GAAFFAR1 | |
| SCHEMBL28320076 | 0.83 | SOAT1 (0.34) | TDP1LMNAHSD17B10GAAFFAR1 | |
| SCHEMBL12274381 | 0.82 | SMPD1 (0.42) | LMNAHSD17B10 | |
| SCHEMBL29637097 | 0.82 | SMPD1 (0.42) | LMNAHSD17B10 | |
| SCHEMBL3449200 | 0.82 | LMNA (0.33) | LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020023823-A1 | BRANCHED REACTIVE BLOCKED PREPOLYMERS FOR ADDITIVE MANUFACTURING | CARBON, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| CN-107474050-B | 6,7- dihydro-pyrazolos [1,5-a] pyrazine -4 (5H) -one compound | 詹森药业有限公司 | 2019-09-10 | — | — | CN | disclosed |
| US-10208062-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-19 | — | — | US | disclosed |
| CN-104039356-B | For chitosan targeted delivery and that small molecule integrin antagonist is covalently attached | 弗·哈夫曼-拉罗切有限公司 | 2018-08-17 | — | — | CN | disclosed |
| CN-105263935-B | 6, 7-dihydropyrazolo [1,5-a ] pyrazin-4 (5H) -one compounds and their use as negative allosteric modulators of the MG L UR2 receptor | 詹森药业有限公司 | 2018-02-27 | — | — | CN | disclosed |
| CN-107474050-A | 6,7 dihydro-pyrazolos [1,5 a] pyrazine 4 (5H) assimilation compound | 詹森药业有限公司 | 2017-12-15 | — | — | CN | disclosed |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| CN-104144706-B | Integrin antagonist conjugates for targeted delivery to alpha-V-beta-3 expressing cells | 弗·哈夫曼-拉罗切有限公司 | 2017-03-29 | — | — | CN | disclosed |
| EP-2044084-B1 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-17 | — | — | EP | disclosed |
| US-8492377-B2 | MTKI quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-23 | — | — | US | disclosed |
| CN-102702193-A | Anti-viral compounds | ABBOTT LAB | 2012-10-03 | — | — | CN | disclosed |
| US-20100152174-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN-CILAG (FR) | 2010-06-17 | — | — | US | disclosed |
| US-20100029627-A1 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-04 | — | — | US | disclosed |
| CN-101421256-A | Thiadiazolidinone inhibitors of ptpase | NOVARTIS AG (CH) | 2009-04-29 | — | — | CN | disclosed |
| EP-2044084-A2 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006884-A2 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-17 | — | — | WO | disclosed |
| EP-1828201-A2 | MACROCYCLIC QUINAZOLINE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-05 | — | — | EP | disclosed |
| CN-1874769-A | Heterocyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2006-12-06 | — | — | CN | disclosed |
| WO-2006061417-A2 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029627-A1 | MTKI QUINAZOLINE DERIVATIVES | NR4A3, NR4A1, NR5A2 | CYP4F2 163/4885CYP4A11 61/4885TDP1 4708/4885 |
| US-20100152174-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR1I2, NR3C2 | CYP4F2 115/4885CYP4A11 66/4885TDP1 4745/4885 |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR3C2, NR1I2 | CYP4F2 144/4885CYP4A11 106/4885TDP1 4773/4885 |
| US-10208062-B2 | Macrocyclic quinazole derivatives and their use as MTKI | NR1I3, NR3C2, NR1I2 | CYP4F2 144/4885CYP4A11 106/4885TDP1 4773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.